News from biopharmadive.com
Media Bias Ratings
Average Bias Rating:
Center
Center
byMedia Bias/Fact CheckDo you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top biopharmadive.com News

Business · United StatesSwiss drugmaker Novartis on Sunday said it agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion in cash. Avidity stockholders will receive $72 per share in cash, representing a premium of 46% to the company's closing on Friday.See the Story
Novartis to acquire Avidity Biosciences for about $12 billion
47% Center coverage: 55 sources

Medical · United StatesThe results could help expand use of Welireg, one of the medicines Merck is counting on to drive revenue growth when its top-selling immunotherapy Keytruda loses patent protection.See the Story
Merck Kidney Cancer Drug Succeeds in Two Large Trials
100% Center coverage: 1 sources
